Phreesia (NYSE:PHR) Price Target Raised to $38.00

Phreesia (NYSE:PHR) had its price objective increased by Canaccord Genuity Group from $34.00 to $38.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other analysts have also recently issued reports on the stock. Truist Financial upped their target price on shares of Phreesia from $34.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, May 29th. Wall Street Zen upgraded shares of Phreesia from a “hold” rating to a “buy” rating in a research report on Sunday, June 1st. Mizuho initiated coverage on shares of Phreesia in a research report on Wednesday, August 27th. They set an “outperform” rating and a $36.00 target price on the stock. DA Davidson initiated coverage on shares of Phreesia in a research report on Friday. They set a “buy” rating and a $33.00 target price on the stock. Finally, Stephens restated an “overweight” rating and set a $32.00 target price on shares of Phreesia in a research report on Wednesday, September 3rd. Thirteen equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $33.31.

Phreesia Stock Down 10.0%

Shares of PHR stock opened at $28.09 on Friday. The stock has a market cap of $1.67 billion, a P/E ratio of -66.88 and a beta of 0.72. Phreesia has a 52 week low of $17.07 and a 52 week high of $32.76. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.02. The company’s fifty day simple moving average is $28.34 and its two-hundred day simple moving average is $26.51.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Thursday, September 4th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.08. The business had revenue of $117.26 million for the quarter, compared to analysts’ expectations of $116.39 million. Phreesia had a negative net margin of 5.35% and a negative return on equity of 9.00%. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. Analysts predict that Phreesia will post -1.1 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider David Linetsky sold 17,445 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $29.73, for a total value of $518,639.85. Following the sale, the insider directly owned 174,002 shares of the company’s stock, valued at $5,173,079.46. This represents a 9.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Lisa Egbuonu-Davis sold 2,802 shares of the stock in a transaction dated Thursday, June 26th. The stock was sold at an average price of $27.67, for a total transaction of $77,531.34. Following the completion of the sale, the director directly owned 22,037 shares in the company, valued at $609,763.79. This trade represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 112,443 shares of company stock worth $3,383,191 over the last three months. 5.50% of the stock is currently owned by company insiders.

Institutional Trading of Phreesia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PHR. Raymond James Financial Inc. purchased a new stake in Phreesia in the 4th quarter worth about $379,000. Hsbc Holdings PLC grew its stake in Phreesia by 36.5% in the 4th quarter. Hsbc Holdings PLC now owns 13,064 shares of the company’s stock worth $333,000 after acquiring an additional 3,493 shares in the last quarter. Northern Trust Corp grew its stake in Phreesia by 6.6% in the 4th quarter. Northern Trust Corp now owns 571,807 shares of the company’s stock worth $14,387,000 after acquiring an additional 35,392 shares in the last quarter. Algert Global LLC grew its stake in Phreesia by 190.1% in the 4th quarter. Algert Global LLC now owns 77,833 shares of the company’s stock worth $1,958,000 after acquiring an additional 51,006 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new position in Phreesia in the 4th quarter worth about $269,000. 92.10% of the stock is owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.